News | November 03, 2007

Alternative Treatment in STEMI Patients Undergoing PCI Looks Promising

November 4, 2007 – A specific way of dosing eptifibatide appears equally effective as giving abciximab as an adjunct to primary percutaneous coronary intervention (PCI) in restoring blood flow to the heart, according to late-breaking clinical trial results announced at the American Heart Association’s Scientific Sessions 2007.

The EVA-AMI study (Eptifibatide Versus Abciximab in Primary PCI for Acute ST elevation Myocardial Infarction) compared the effectiveness of giving a double bolus of eptifibatide versus abciximab in achieving complete electrocardiographic ST resolution 60 minutes after PCI. (Complete ST resolution means a greater than 70 percent resolution of the ST segment elevation seen on the patient’s initial electrocardiogram.) Standard treatment after a heart attack often includes PCI, or angioplasty, to re-open the blocked artery that caused the attack. After PCI, patients are typically prescribed medicine to reduce the risk of blood clots. The drugs eptifibatide and abciximab are both glycoprotein IIb/IIIa inhibitors, which prevent platelets from sticking together to form blood clots.

“Complete ST resolution is a sign that blood is getting through to the heart muscle. It is closely related to 30-day and long-term mortality,” said Uwe Zeymer, lead author of the study, which was conducted out of Ludwigshafen, Germany. “Our results show there were no differences between the effectiveness of the two drugs.”

EVA-AMI is an international, multicenter, randomized, prospective, open parallel group comparison of the two drugs in patients undergoing primary PCI less than 12 hours after having a heart attack. The study included 430 patients in France and Germany between November 2006 and May 2007.

The patients were also taking clopidogrel (another antiplatelet) and aspirin, plus heparin (a blood thinner) or enoxaparin (a low molecular weight heparin), which are all part of standard treatment after a heart attack.

Support for this study was provided by Glaxo Smith Kline.

Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The American Heart Association makes no representation or warranty as to their accuracy or reliability.

For more information:

Related Content

Resolute Onyx Stent With Improved Radiographic Visibility Found to Be Safe and Effective
News | Stents Drug Eluting | October 01, 2018
October 1, 2018 — Recent results from the BIONYX randomized clinical study showed the novel, thin-strutted, polymer-c
Boston Scientific Receives FDA Approval for Eluvia Drug-Eluting Vascular Stent
Technology | Stents Drug Eluting | October 01, 2018
Boston Scientific announced that the U.S. Food and Drug Administration (FDA) has approved its Premarket Approval (PMA)...
Eluvia Drug-Eluting Stent Demonstrates Superior Patency in IMPERIAL Trial
News | Stents Drug Eluting | September 26, 2018
Positive 12-month data from the late-breaking IMPERIAL trial was presented at the 2018 Transcatheter Cardiovascular...
Titanium-Nitride-Oxide Stent Superior to Bioabsorbable DES in Acute Coronary Syndrome Patients

Image courtesy of Hexacath

News | Stents Drug Eluting | May 31, 2018
Late-breaking trial results presented at the EuroPCR Congress, May 21-24 in Paris, France, found the Optimax titanium-...
Orsiro DES Shows Lowest Two-Year Target Lesion Failure in BIO-RESORT Trial
News | Stents Drug Eluting | May 31, 2018
Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-breaking clinical trials...
OCT Reveals Excellent Healing Profile for Complex CAD Patients With Resolute Onyx DES
News | Stents Drug Eluting | May 29, 2018
Investigators recently unveiled clinical data from the independently run Onyx 1-Month OCT Study showing strong early...
Abbott's Xience Sierra Stent Receives FDA Approval
Technology | Stents Drug Eluting | May 25, 2018
Abbott announced it received approval from the U.S. Food and Drug Administration (FDA) for Xience Sierra, the newest...
Medtronic Launches 2 mm Onyx DES
Technology | Stents Drug Eluting | February 26, 2018
February 26, 2018 – Designed specifically for small vessels, Medtronic plc announced U.S.
Detroit Medical Center Heart Hospital Uses Michigan's First EluNIR Drug-Eluting Stent
News | Stents Drug Eluting | February 19, 2018
February 19, 2018 — The Detroit Medical Center’s (DMC) interventional cardiology team at Heart Hospital recently beca
Biotronik Symposium Highlights Differing Roles of Drug-Eluting Stents and Magnesium Scaffolds in Clinical Practice
News | Stents Drug Eluting | January 25, 2018
January 25, 2018 – Data presented at the Biotronik-sponsored...
Overlay Init